Given the pivotal role of the MAdCAM-1/α4β7 pathway in sustaining this gut-liver inflammatory axis, monoclonal antibodies targeting this pathway, such as Vedolizumab, have emerged as a key therapeutic strategy for IBD [6]. This evidence concerns the gene MADCAM1 and inflammatory bowel disease.